Multichannel Marketing: Easy to Brag About, but Difficult to Do
Multichannel pharma marketing is conceptually relatively simple to understand, but incredibly difficult in practice, says Len Starnes, former Head of Digital Marketing & Sales, General Medicine at Bayer Schering Pharma. That said, multichannel is not a transient phenomenon, it's here to stay. Starnes hosted a survey on LinkedIn to answer the question: When will pharma marketing become de facto multichannel marketing in future?
Multichannel Marketing: Easy to Brag About, but Difficult to Do
Multichannel pharma marketing is conceptually relatively simple to understand, but incredibly difficult in practice, says Len Starnes, former Head of Digital Marketing & Sales, General Medicine at Bayer Schering Pharma. That said, multichannel is not a transient phenomenon, it's here to stay. Starnes hosted a survey on LinkedIn to answer the question: When will pharma marketing become de facto multichannel marketing in future?
Multichannel Marketing: Easy to Brag About, but Difficult to Do
Multichannel pharma marketing is conceptually relatively simple to understand, but incredibly difficult in practice, says Len Starnes, former Head of Digital Marketing & Sales, General Medicine at Bayer Schering Pharma. That said, multichannel is not a transient phenomenon, it's here to stay. Starnes hosted a survey on LinkedIn to answer the question: When will pharma marketing become de facto multichannel marketing in future?
Supporting Patients via Twitter and Beyond
Although nearly two-thirds of respondents to a 2009/2010 Pharma Marketing News survey thought that using Twitter for patient support activities would be somewhat or very effective, relatively few pharmaceutical companies are doing this on a regular basis. From time to time, however, it does happen. Boehringer Ingelheim Shows How It's Done
Supporting Patients via Twitter and Beyond
Although nearly two-thirds of respondents to a 2009/2010 Pharma Marketing News survey thought that using Twitter for patient support activities would be somewhat or very effective, relatively few pharmaceutical companies are doing this on a regular basis. From time to time, however, it does happen. Boehringer Ingelheim Shows How It's Done
Are Some DTC Print Ads Too Educational and/or Persuasive?
FDA Plans to Do Two Studies to Find Out
Are Some DTC Print Ads Too Educational and/or Persuasive?
FDA Plans to Do Two Studies to Find Out
Are Some DTC Print Ads Too Educational and/or Persuasive?
FDA Plans to Do Two Studies to Find Out
Are Some DTC Print Ads Too Educational and/or Persuasive?
FDA Plans to Do Two Studies to Find Out
Pharma Marketing News Vol. 11, No. 6: 29 June 2012
Welcome to Volume 11, Issue #6 (29 JUNE 2012) of Pharma Marketing News.
